Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aldagen Inc.

Division of Nuo Therapeutics Inc.
www.aldagen.com

Latest From Aldagen Inc.

Aldea raises $24m for alcohol detox, anemia drug

Aldea Pharmaceuticals will begin clinical trials in acute alcohol intoxication and Fanconi anemia for AD-6626, the company's lead drug candidate for aldehyde metabolism disorders, with $24m in Series B venture capital from new Russian and Chinese investors and existing US-based VC backers.

Metabolic Disorders Gastrointestinal

Stroke candidate to feel brunt of Cytomedix restructure

Cytomedix is to downsize its R&D activities in a renewed focus on profitability, in what is its second reorganization in as many months.

Dermatology Wound Healing & Tissue Repair

Cytomedix falls 25% as it turns to three-pronged financing plan

Cytomedix stock lost 25% of its value on 20 February when the Gaithersburg, Maryland-based company specializing in autologous regenerative therapies announced three different financing vehicles designed to generate up to $27.5 million for its "2013 operational business plan."

Dermatology Wound Healing & Tissue Repair

Deals Shaping The Medical Industry (03/2012)

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • StemCo Biomedical Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Nuo Therapeutics Inc.
  • Senior Management
  • Lyle Hohnke, PhD, CEO
    Edward J Field, COO
    James M Hinson, Jr., MD, CMO
  • Contact Info
  • Aldagen Inc.
    Phone: (919) 484-2571
    2810 Meridian Pkwy
    Ste. 148
    Durham, NC 27713
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register